[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 34.204.176.189. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 199
Citations 0
Correction
June 2019

Error in Abstract

JAMA Neurol. 2019;76(6):732. doi:10.1001/jamaneurol.2019.1455

In the Original Investigation by Joseph et al titled “Fractures and Linear Growth in a Nationwide Cohort of Boys With Duchenne Muscular Dystrophy With and Without Glucocorticoid Treatment: Results From the UK NorthStar Database,” published online March 11, 2019, and also in the June print issue of JAMA Neurology,1 there was an error in the Results section of the Abstract. The fifth sentence should read, “After adjusting for age at last visit, mean hydrocortisone equivalent dose, mobility status, and bisphosphonate use prior to first fracture, boys treated with daily deflazacort had a 16.0-fold increased risk for first fracture (95% CI, 1.4-180.8; P = .03).” This article was corrected online. This article was also corrected in April 2019 to fix a group author that was incorrectly categorized.2

References
1.
Joseph  S, Wang  C, Bushby  K,  et al.  UK NorthStar Clinical Network. Fractures and linear growth in a nationwide cohort of boys with Duchenne muscular dystrophy with and without glucocorticoid treatment: results from the UK NorthStar Database  [published online March 11, 2019].  JAMA Neurol. doi:10.1001/jamaneurol.2019.0242Google Scholar
2.
 Incorrectly categorized group author  [published online April 15, 2019].  JAMA Neurol. doi:10.1001/jamaneurol.2019.0904Google Scholar
×